Charles Schwab Investment Management Inc. Takes $796,000 Position in Maze Therapeutics, Inc. $MAZE

Charles Schwab Investment Management Inc. purchased a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 72,305 shares of the company's stock, valued at approximately $796,000. Charles Schwab Investment Management Inc. owned 0.17% of Maze Therapeutics as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. New York State Common Retirement Fund bought a new stake in shares of Maze Therapeutics in the first quarter worth about $25,000. Bank of New York Mellon Corp bought a new stake in shares of Maze Therapeutics in the first quarter worth about $190,000. Bessemer Group Inc. bought a new stake in shares of Maze Therapeutics in the first quarter worth about $5,305,000. Harvard Management Co. Inc. bought a new stake in shares of Maze Therapeutics in the first quarter worth about $7,019,000. Finally, General Catalyst Group Management LLC bought a new stake in shares of Maze Therapeutics in the first quarter worth about $11,405,000.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on MAZE. Wall Street Zen raised Maze Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. BTIG Research began coverage on Maze Therapeutics in a report on Tuesday, September 2nd. They issued a "buy" rating and a $30.00 target price on the stock. HC Wainwright began coverage on Maze Therapeutics in a report on Wednesday, July 23rd. They issued a "buy" rating and a $34.00 target price on the stock. Finally, Wedbush started coverage on Maze Therapeutics in a report on Tuesday, July 8th. They issued an "outperform" rating and a $17.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $26.33.

Maze Therapeutics Trading Up 5.6%

NASDAQ MAZE traded up $0.84 during trading hours on Friday, hitting $15.88. 309,623 shares of the company were exchanged, compared to its average volume of 322,211. The stock has a 50-day moving average price of $14.55 and a 200 day moving average price of $12.01. Maze Therapeutics, Inc. has a 52 week low of $6.71 and a 52 week high of $19.19.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.02.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.